Your browser is old and is not supported. Upgrade for better security.

Invest in BioSuperior Technology, Inc.

Our mission is to revolutionize pulmonary care and save lives by curing lung disease

Pitch Video
Investor Panel

Highlights

1
We expect our synthetic lung surfactant to transform medical care for pre-term babies with breathing problems.
2
Further, we plan to use BioSURF as a drug delivery platform for other critical diseases.
3
We are actively working on a gene therapy that repairs injured lungs following exposure to pathogens like SARS-CoV-2.
4
We have prototypes for each of these products. These are first-ever achievements.
5
Our team of scientists average 20 years of experience and have developed drugs that sell more than $1B/yr.
6
Our team is strongly qualified in our ability to work with the FDA and bring drugs to market.
7
We have strong endorsement from leading Physicians at Stanford School of Medicine and Cincinnati Children's Hospital.
8
We are currently funded by the March of Dimes, and the National Science Foundation

Our Team

Several of us have had family members develop serious illness and pass as a result of Acute Lung Injury. We are deeply concerned with the standard of care in respiratory medicine and believe that we can substantively improve this situation.

Pitch


Downloads

Overview